A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing

Dr Vail shares insight into his ideal institutional approach to biomarker testing for NSCLC, emphasizing the need for local molecular pathology expertise and available in-house biomarker panels.

EP: 1.An Introduction to Biomarker Testing in Non-Small Cell Lung Cancer

EP: 2.Analyzing the Relationship Between Biomarkers, Testing Rates, and Clinical Characteristics in Non-Small Cell Lung Cancer

EP: 3.Available Biomarker Testing Modalities for Patients with mNSCLC

EP: 4.Clinical Experience with Coordinating Biomarker Testing for Patients with mNSCLC

EP: 5.Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLC

Now Viewing

EP: 6.A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing

EP: 7.Challenges of Using Biomarker Testing in mNSCLC

EP: 8.An Introduction to Three Real-World Analyses of Biomarker Testing Patterns in mNSCLC

EP: 9.Overcoming Disparities in Biomarker Testing Use for mNSCLC

EP: 10.Patient Case 2: mNSCLC with an EGFR Exon 20 Insertion

EP: 11.Managing Disease Progression in Patients with EGFR-mutated mNSCLC

EP: 12.CHRYSALIS: Study Design and Key Results for Amivantamab in mNSCLC

EP: 13.Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC

EP: 14.Data-Informed Insights on Second-line Treatment Selection for EGFR Exon 20-mutated mNSCLC

EP: 15.Patient Case 2: Second-line Treatment Selection and Adverse Event Management

EP: 16.Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC

EP: 17.Key Takeaways Regarding Biomarker Testing for mNSCLC

Related Videos